NEW YORK, NY August 10, 2015 8:30 AM Celgene Corporation (CELG) exercised its option under the 2009 Collaboration and Option Agreement to exclusively license GI-6207, a Tarmogen® product candidate targeting cancers that express carcinoembryonic antigen...
via Business - United States - Latest News http://ift.tt/1N3zeQi
No comments:
Post a Comment